Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer

Published:2024-05-31 Issue:11 Volume:25 Page:6058
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Chamorey Emmanuel¹^ORCID,Pujalte-Martin Marc²^ORCID,Ferrero Jean-Marc²,Mahammedi Hakim³,Gravis Gwenaelle⁴,Roubaud Guilhem⁵,Beuzeboc Philippe⁶,Largillier Remy⁷,Borchiellini Delphine²⁸,Linassier Claude⁹,Bouges Hélène¹⁰,Etienne-Grimaldi Marie-Christine¹⁰^ORCID,Schiappa Renaud¹^ORCID,Gal Jocelyn¹^ORCID,Milano Gérard¹⁰

Affiliation:

1. Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d’Azur, 06000 Nice, France

2. Medical Oncology Department, Centre Antoine Lacassagne, University Côte d’Azur, 06000 Nice, France

3. Medical Oncology Department, Centre Jean Perrin, 63000 Clermond Ferrand, France

4. Medical Oncology Department, Institut Paoli Calmette, 13009 Marseille, France

5. Department of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France

6. Medical Oncology Department, Institut Curie, 75005 Paris, France

7. Medical Oncology Department, Centre Azuréen de Cancérologie, 06250 Mougins, France

8. Clinical Research Department, Centre Antoine Lacassagne, University Côte d’Azur, 06000 Nice, France

9. Medical Oncology Department, Centre Hospitalier Régional Universitaire, 37000 Tours, France

10. Oncopharmacology Unit, Centre Antoine Lacassagne, University Côte d’Azur, 06189 Nice, France

Abstract

This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (p = 0.041). The safety data did not correlate with the AA PK data. A significant positive correlation (r = 0.40, p < 0.001) was observed between mean AA concentration and patient age: the older the patient, the higher the AA concentration. Patient age was found to impact steady-state AA concentration: the older the patient, the higher the mean AA concentration. Altogether, these data may help to guide future research and clinical trials in order to maximize the benefits of AA metastatic castration-resistant prostate cancer patients.

Funder

JNASSEN

Publisher

MDPI AG

Link

https://www.mdpi.com/1422-0067/25/11/6058/pdf

Reference26 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N. Engl. J. Med.,2004

2. Abiraterone and increased survival in metastatic prostate cancer;Logothetis;N. Engl. J. Med.,2011

3. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial;Logothetis;Lancet Oncol.,2012

4. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer;Judson;Br. J. Cancer,2004

5. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients;Carton;Eur. J. Cancer,2017